Biomira Closes Enrolment in Theratope(R) Vaccine Phase III Trial

Apr 02, 2001, 01:00 ET from Biomira Inc.

    EDMONTON, April 2 /PRNewswire/ - Biomira Inc. (Nasdaq:  BIOM) (TSE:BRA)
 announced today that enrolment is officially closed in the Company's Phase III
 THERATOPE(R) vaccine trial for metastatic breast cancer. Enrolment for the
 trial closed at 12:00 p.m. EST, Friday, March 30, 2001.
     At the time of closure, enrolment had surpassed the 1,000 patient mark.
 The Company announced at the beginning of March that it had enrolled the 950
 patients specified in the protocol, but kept the trial open so that patients
 being screened had the opportunity to participate in the trial.
     "The closing of Biomira's Phase III THERATOPE(R) vaccine trial signifies
 that we are one important step closer to our goal of commercializing our lead
 immunotherapeutic product," commented Alex McPherson, MD, PhD, President and
 CEO. "We are encouraged by the rapid increase in patient entry over the last
 few months of the trial. This suggests patients and investigators are
 enthusiastic about our approach to fighting cancer."
     The THERATOPE(R) vaccine Phase III trial is a survival trial with final
 analysis of data expected to commence in mid-2003. However, Biomira has
 planned two interim analyses for the THERATOPE(R) vaccine trial to take
 advantage of the potential to make this product candidate available to cancer
 patients as soon as possible, should statistical significance be seen at
 either of these two points. The first of these analyses is anticipated to be
 initiated in the third quarter of 2001.
     The precise timing of the first interim analysis, as well as the second
 and the final analyses are dependent upon a statistical model that requires a
 pre-determined number of events in each of the two primary endpoints (disease
 progression and survival).
     Biomira is a biotechnology company specializing in the development of
 innovative therapeutic approaches to cancer management. The commitment to the
 treatment of cancer currently focuses on the development of synthetic vaccines
 and novel strategies for cancer immunotherapy. We are The Cancer Vaccine
 People(TM).
 
     This release may contain forward-looking statements.  Various factors
 could cause actual results to differ materially from those projected in
 forward-looking statements, including those predicting the timing of clinical
 trials, trial reviews and analyses or the efficacy of products.  Although the
 Company believes that the forward-looking statements contained herein are
 reasonable, it can give no assurance that the Company's expectations are
 correct.  All forward-looking statements are expressly qualified in their
 entirety by this cautionary statement.
 
 

SOURCE Biomira Inc.
    EDMONTON, April 2 /PRNewswire/ - Biomira Inc. (Nasdaq:  BIOM) (TSE:BRA)
 announced today that enrolment is officially closed in the Company's Phase III
 THERATOPE(R) vaccine trial for metastatic breast cancer. Enrolment for the
 trial closed at 12:00 p.m. EST, Friday, March 30, 2001.
     At the time of closure, enrolment had surpassed the 1,000 patient mark.
 The Company announced at the beginning of March that it had enrolled the 950
 patients specified in the protocol, but kept the trial open so that patients
 being screened had the opportunity to participate in the trial.
     "The closing of Biomira's Phase III THERATOPE(R) vaccine trial signifies
 that we are one important step closer to our goal of commercializing our lead
 immunotherapeutic product," commented Alex McPherson, MD, PhD, President and
 CEO. "We are encouraged by the rapid increase in patient entry over the last
 few months of the trial. This suggests patients and investigators are
 enthusiastic about our approach to fighting cancer."
     The THERATOPE(R) vaccine Phase III trial is a survival trial with final
 analysis of data expected to commence in mid-2003. However, Biomira has
 planned two interim analyses for the THERATOPE(R) vaccine trial to take
 advantage of the potential to make this product candidate available to cancer
 patients as soon as possible, should statistical significance be seen at
 either of these two points. The first of these analyses is anticipated to be
 initiated in the third quarter of 2001.
     The precise timing of the first interim analysis, as well as the second
 and the final analyses are dependent upon a statistical model that requires a
 pre-determined number of events in each of the two primary endpoints (disease
 progression and survival).
     Biomira is a biotechnology company specializing in the development of
 innovative therapeutic approaches to cancer management. The commitment to the
 treatment of cancer currently focuses on the development of synthetic vaccines
 and novel strategies for cancer immunotherapy. We are The Cancer Vaccine
 People(TM).
 
     This release may contain forward-looking statements.  Various factors
 could cause actual results to differ materially from those projected in
 forward-looking statements, including those predicting the timing of clinical
 trials, trial reviews and analyses or the efficacy of products.  Although the
 Company believes that the forward-looking statements contained herein are
 reasonable, it can give no assurance that the Company's expectations are
 correct.  All forward-looking statements are expressly qualified in their
 entirety by this cautionary statement.
 
 SOURCE Biomira Inc.